By Fineline Cube 
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
BRUIN CLL-321 Study Design and Primary Endpoint
The BRUIN CLL-321 study is designed to assess the efficacy of pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. The study has already met its primary endpoint of progression-free survival (PFS) at the preliminary analysis, with pirtobrutinib showing superiority over the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
Consistent Improvement in Progression-Free Survival
The final prespecified analysis results revealed at ASH 2024 demonstrated consistent improvement in PFS for patients treated with pirtobrutinib. The treatment reduced the risk of relapse, disease progression, or death by 46% compared to IdelaR or BR, highlighting the potential of pirtobrutinib as a more effective therapy for patients with CLL/SLL who have previously received a covalent BTK inhibitor.-Fineline Info & Tech